The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next 10 years. The well-established TNF-α inhibitors (e.g., infliximab, adalimumab [AbbVie / Eisai’s Humira, biosimilars]), together with non-TNF biologics (i.e., Takeda’s Entyvio and Janssen’s Stelara), have transformed the treatment landscape for CD, especially for moderate to severe disease, despite these drugs’ efficacy limitations and safety risks. The impending entry of several new therapies offering more-convenient formulations and/or novel mechanisms of action (e.g., AbbVie’s Skyrizi and Rinvoq, Eli Lilly’s mirikizumab, Janssen’s Tremfya) will further improve treatment and intensify market competition. Together with these trends, the continuing generic erosion of conventional agents and the availability of biosimilar TNF-α inhibitors will constrain CD therapy sales.
Geographies: United States, EU5, Japan.
Primary research: 25 country-specific interviews with thought-leading gastroenterologists supported by survey data collected for this and other Clarivate research.
Epidemiology: Diagnosed prevalence of CD by country, segmented by disease activity.
Forecast: 10-year, annualized, drug-level sales and patient share of key CD therapies through 2031, segmented by brands/generics.
Emerging therapies: Phase III/preregistered: ~8 drugs; coverage of select Phase I and Phase II products.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast features continual updates to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.